Esophageal cancer, Hepatocellular carcinoma, Intrahepatic bile duct cancer
Conditions
Interventions
None listed
Sponsors
National Institutes for Quantum Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Persons aged 18 or over at the time of obtaining consent. Gender is not a consideration. 2) Those who have been diagnosed with esophageal cancer, hepatocellular carcinoma, or intrahepatic bile duct cancer and will undergo carbon ion radiotherapy. 3) Those who are expected to have their heart included in the irradiation field, as described in 2). 4) Those who can regularly visit QST Hospital for at least two years after the end of carbon ion beam irradiation. 5) Those who are judged by the researcher to be able to understand the consent document.
Exclusion criteria
Exclusion criteria: 1) People who cannot have an MRI scan due to claustrophobia, pacemakers, or magnetic metals in the body. 2) People with a history of contrast agent allergies, or people with low kidney function who cannot have a contrast MRI scan. 3) People with serious complications, or people who have a history of these complications and who are judged by the researcher to be unsuitable for this study. 4) Those who are pregnant or may be pregnant, or who are breastfeeding. 5) Others who are judged by the researcher to be unsuitable as a research subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of Grade 3 or higher cardiac adverse events occurring between 3 and 24 months after the end of carbon-ion radhiotherapy | — |
Countries
Japan
Contacts
Public ContactTetsuro Isozaki
National Institutes for Quantum Science and Technology QST Hospital Department of Radiology
Outcome results
None listed